Explore IQVIA by region
As a global community, IQVIA continuously invests and commits to advancing human health.
Europe
Asia & Oceania
Middle East & Africa
EMEA Thought Leadership
Life Sciences Solutions
Bringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn More
Commercial Solutions
Commercial Solutions (desc)
Contract Sales and Medical Solutions
Contract Sales and Medical Solutions (desc)
Financial Services
Financial Services (desc)
Information Solutions
Information Solutions (desc)
Medical Affairs
Medical Affairs (desc)
Real World Evidence
Real World Evidence (desc)
Healthcare Solutions
Accelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn More
Medical Device and Diagnostic Solutions
Your world is unique – and quite different from pharma. In the U.S., decision-making has shifted from individual physicians to integrated networks--GPOs, IDNs and payers. These groups have heightened the focus on proving your solution’s value, demanding outcomes analyses and putting pressure on pricing.
Learn More
U.S. Government Solutions
For government agencies and organizations at every level—from federal or national to regional and local—Big Data can have a huge impact on public health.
Learn More
The IQVIA difference
Explore IQVIA by region
As a global community, IQVIA continuously invests and commits to advancing human health.
Americas
Europe
Asia & Oceania
Middle East & Africa
EMEA Thought Leadership
White Paper
The 340B Drug Discount Program: Complexity, Challenges, and Change
Learn more about the 340B program, how it's evolving, potential challenges, and possible strategies to mitigate its impact on gross-to-net.
Sep 01, 2020
- Locations
- United States
- The 340B Drug Discount Program
The combination of COVID-19, specialty growth,the rise of contract pharmacies, and more effective covered entity strategies is creating a perfect storm for manufacturers. It is vital they understand the 340B program and arm themselves with solutions that shed light on how it is impacting their business and develop more advanced strategies to ensure proper program usage. This is the first in a series of articles about the 340B program from IQVIA's Market Access Center of Excellence (CoE).